Clinical trials: Testicular Cancer
Non Small Cell Lung Cancer
CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
- Trial name
- NCT03571360
- Testing
- PD-L1 positive vs PD-L1 negative NSCLC patients
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Medical University of Vienna